Clinical Knowledge
What's new in veterinary medicine.
Evidence-based clinical briefings — new findings, updated guidelines, and protocols, cited at every claim. Reviewed by board-certified DVMs.
Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evidence from pivotal RCTs, a 12-month cohort, and combination therapy data reviewed.
Read →Robenacoxib (Onsior) for Pain in Cats and Dogs: COX-2 Selectivity and Clinical Evidence
Robenacoxib (Onsior) is a COX-2-selective NSAID with tissue-preferential distribution. Evidence from a feline DJD RCT and perioperative comparison data reviewed.
Read →Update (June 9, 2026): Rapamycin Impairs Platelet Aggregation and Procoagulant Phenotypes in Cats Ex Vivo
See article body for full excerpt.
Read →Update (June 9, 2026): FDA ADAE Disproportionality Analysis Identifies 19 Frunevetmab AE Signals in Cats
See article body for full excerpt.
Read →Update (June 9, 2026): Comprehensive Feline Therapeutics Review Covers Capromorelin in CKD Context
See article body for full excerpt.
Read →Update (June 9, 2026): Combination Oclacitinib and Lokivetmab After Monotherapy Failure in 44 Dogs
See article body for full excerpt.
Read →Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval and Clinical Evidence
See article body for full excerpt.
Read →Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety
Atopica for Cats produced a 65.1% lesion score reduction vs 9.2% in controls in a 181-cat field study. FDA-indicated for miliary dermatitis, eosinophilic plaques, excoriations, and self-induced alopecia.
Read →Rapamycin (Sirolimus) for Feline Hypertrophic Cardiomyopathy: RAPACAT Trial and Evidence
The RAPACAT trial — a double-blind, multicenter RCT — showed significantly lower LV wall thickness at Day 180 with low-dose delayed-release rapamycin vs placebo (P=0.01) in cats with subclinical HCM.
Read →Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
Two controlled studies confirm 98–100% mite-free rates with a single fluralaner administration for canine generalized demodicosis, outperforming imidacloprid/moxidectin.
Read →Update (June 8, 2026): First Multicenter RCT of Imepitoin in Feline Idiopathic Epilepsy
Charalambous 2026 (Front Vet Sci): imepitoin achieved 62% responder rate in 37 cats with idiopathic epilepsy; phenobarbital showed higher 90% rate. First placebo-controlled trial in cats.
Read →Update (June 8, 2026): Gabapentin + Ciclosporin in Feline Atopic Skin Syndrome — New RCT
Morency 2025 (Vet Dermatol): gabapentin reduced FeDESI across all FASS treatment groups (P<0.001, IRR 2.59 vs placebo); ciclosporin required gabapentin addition to achieve significance.
Read →Update (June 8, 2026): Capromorelin (Elura) Approved for CKD Weight Loss in Cats — RCT Data
Wofford 2025 multicenter RCT: capromorelin (Elura, NADA 141-536) produced +5.18% body weight vs -1.65% placebo at Day 55 in 176 CKD cats (treatment effect +6.81%, P<0.0001).
Read →Imepitoin (Pexion) for Canine Idiopathic Epilepsy: Evidence Review
Imepitoin is a partial benzodiazepine receptor agonist approved in Europe for canine idiopathic epilepsy; 47% seizure-free rate in pivotal field trial; fav
Read →Trilostane (Vetoryl) for Canine Hyperadrenocorticism: Evidence and Monitoring
Trilostane (Vetoryl) inhibits 3-beta-hydroxysteroid dehydrogenase for canine HAC; polyuria resolved in 70%, skin changes in 62%; pre-trilostane cortisol ma
Read →Robenacoxib (Onsior) for Pain and Inflammation in Dogs and Cats
Robenacoxib (Onsior) is a highly COX-2-selective NSAID (COX-1:COX-2 IC50 ratio 502 in cats) with tissue-selective exudate distribution; noninferior to melo
Read →Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use
Cyclosporine (Atopica, NADA 141-218) FDA-approved for canine atopic dermatitis; CADESI improved 45% vs placebo at 30 days; concurrent short-course predniso
Read →Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence
Evidence-based review of maropitant (Cerenia) efficacy for canine motion sickness and feline CKD vomiting, with NK1 mechanism and label information.
Read →Gabapentin for Pre-Visit Feline Anxiety: Evidence and Clinical Use
Randomized and systematic-review evidence on gabapentin for reducing feline stress and anxiety during transport and veterinary examination.
Read →Mirtazapine Transdermal Ointment (Mirataz) for Feline Weight Loss
FDA-approved mirtazapine transdermal ointment (Mirataz) for feline weight loss: pivotal field study results, mechanism, CKD and oncology evidence.
Read →Telmisartan (Semintra) for Proteinuria and Hypertension in Cats with CKD
Telmisartan (Semintra) for feline CKD proteinuria and hypertension: multicenter RCT vs benazepril, FDA and EMA approval, ARB mechanism, and monitoring guidance.
Read →Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
Oclacitinib (Apoquel) for canine atopic dermatitis: 24-hour onset RCT data, comparison with prednisolone and ciclosporin, JAK1 mechanism, and monitoring guidance.
Read →Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
Grapiprant (Galliprant) for canine osteoarthritis: EP4 receptor antagonism mechanism, pivotal JVIM field study (48.1% vs 31.3% success), FDA/EMA approval, and comparison with meloxicam.
Read →Capromorelin (Entyce) for Appetite Stimulation in Dogs: Evidence and Clinical Use
FDA-approved capromorelin (Entyce) for canine appetite stimulation: pivotal field study, Beagle dose-response data, ghrelin receptor mechanism, and Elura feline CKD indication.
Read →Frunevetmab (Solensia) for Feline Osteoarthritis: Effectiveness and Real-World Safety
Frunevetmab (Solensia) for feline OA pain: real-world quality-of-life benefit and an FDA-database adverse-event profile (mostly dermatological).
Read →Verdinexor (Laverdia) for Canine Lymphoma: Mechanism and Evidence
Verdinexor (Laverdia-CA1), an oral XPO1/nuclear-export inhibitor for canine lymphoma: mechanism, an 8-dog cutaneous T-cell pilot, and combination data.
Read →Update (June 5, 2026): The Controlled Field-Study Efficacy Behind Bedinvetmab (Librela)
Peer-reviewed field studies behind Librela: US 47.4% vs 36.6% (p=0.041) and EU 43.5% vs 16.9% (p=0.0017) Day-28 treatment success.
Read →Tasipimidine (Tessie) for Noise Aversion and Separation Anxiety in Dogs
First FDA-approved drug for both noise aversion and separation anxiety in dogs. Alpha-2 agonist mechanism, oral solution, May 2026 approval.
Read →Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile
FDA label (2025) lists neurological AEs for bedinvetmab: ataxia, seizures, paresis. 17,911 reports filed. NSAID co-use precaution. Efficacy and PK summary.
Read →Pregabalin for Chiari-like Malformation and Syringomyelia Pain in Dogs
Evidence summary on pregabalin for canine CM/SM neuropathic pain: a randomized placebo-controlled crossover study, disease course, and other options.
Read →